Radiofrequency catheter ablation of type 1 atrial flutter using large-tip 8- or 10-mm electrode catheters and a high-output radiofrequency energy generator Results of a multicenter safety and efficacy study by Feld, Gregory et al.
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nd Boston, Massachusetts
OBJECTIVES We studied the safety and efficacy of atrial flutter (AFL) ablation using 8- or 10-mm electrode
catheters and a 100-W radiofrequency (RF) generator.
BACKGROUND Large-tip electrode catheters may be more effective for ablation of AFL.
METHODS There were 169 patients (age 61  12 years). Short-term end points were bidirectional
isthmus block and no inducible AFL. After ablation, patients were seen at one, three, and six
months, with event monitoring performed weekly and for any symptoms. Three quality-of-
life (QOL) surveys were completed during follow-up.
RESULTS Short-term success was achieved in 158 patients (93%), with 12  11 RF applications. The
efficacy of 8- and 10-mm electrodes was similar (p  NS). The number of RF applications
(10  8 vs. 14  8) and ablation time (0.5  0.4 h vs. 0.8  0.6 h) were less with the 10-
versus 8-mm electrode, respectively (p  0.01). Of 158 patients with short-term success, 42
patients were not evaluated for success at six months because of study exclusions. Of 116
patients with short-term success evaluated at six months, 112 (97%) patients had no AFL
recurrence. Of those without AFL recurrence at six months, 95% and 93% remained free of
symptoms at 12 and 24 months, respectively. Ablation of AFL improved QOL scores (p 
0.05) and reduced anti-arrhythmic and rate-control drug use (p  0.05). Complications
occurred in 6 (3.6%) of 169 patients, but there were no deaths.
CONCLUSIONS Ablation of AFL with 8- or 10-mm electrode catheters and a high-power RF generator was
safe and effective and improved QOL. The number and duration of RF applications were
lower with 10- versus 8-mm electrode catheters. (J Am Coll Cardiol 2004;43:1466–72)
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rtrial flutter (AFL) is a common arrhythmia that can be
ured by radiofrequency (RF) catheter ablation of the
ricuspid valve (TV)-inferior vena cava (IVC) isthmus
1–8). With the demonstration of bidirectional conduction
lock across the TV-IVC isthmus after ablation, long-term
fficacy has increased to 90% (9). Nevertheless, when
sing standard 4- and 5-mm electrode-tipped catheters and
n RF generator with a maximum power of 50 W, ablation
ay be difficult in some cases, requiring multiple energy
pplications and prolonged procedure and fluoroscopy times
1–9). Consequently, the efficacy of ablation catheters with
onger electrodes (i.e., 5 mm), or saline irrigated elec-
rodes has been investigated (10–14). Large-tip ablation
atheters and irrigated tip ablation catheters have a theoret-
cal advantage because they can produce a larger ablation
esion (14). However, in the case of longer ablation elec-
From the *University of California, San Diego, California; †Duke University,
urham, North Carolina; ‡University of Alabama, Birmingham, Alabama; §Grant
iverside Hospital, Columbus, Ohio; Inova Fairfax Hospital, Falls Church, Virginia;
Brigham and Women’s Hospital, Boston, Massachusetts. See the Appendix for a list
f investigators and affiliations. This study was sponsored by Boston Scientific
orporation. Dr. Albert L. Waldo acted as the Guest Editor for this paper.
Manuscript received June 17, 2003; revised manuscript received October 24, 2003,Accepted November 12, 2003.rodes that have a larger surface area, a higher power RF
enerator (i.e., 50 W) is required to produce adequate
blation temperatures (15). The potential advantages of
sing large-tip electrode ablation catheters with a high
ower RF generator include the need for fewer energy
pplications to produce bidirectional isthmus block, shorter
rocedure and fluoroscopy times, and greater efficacy.
Therefore, we investigated the safety and efficacy of AFL
blation using 8- and 10-mm electrode ablation catheters
nd a high output 100-W RF generator in a multi-center
tudy.
ETHODS
his study was designed to evaluate the safety and efficacy of
he EPT-1000 XP Cardiac Ablation System (Boston Sci-
ntific Corp., Natick, Massachusetts), consisting of 8- or
0-mm ablation electrode catheters and a 100-W RF
enerator for ablation of type 1 AFL, in a multicenter,
rospective registry. The primary study end points were
hort- and long-term (six-month) success, defined as bidi-
ectional isthmus block and a lack of recurrence of type 1
FL, respectively. An additional end point was the com-
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April 21, 2004:1466–72 Ablation of AFL With Large-Tip Catheterslication rate. Patients were followed after ablation, using
linical parameters and event monitoring to detect symp-
omatic and asymptomatic recurrences of AFL. Several
uality-of-life (QOL) parameters were also evaluated.
Study inclusion criteria included: 1) AFL defined as an
trial rate between 240 and 350 beats/min, unless modified
y class 1c anti-arrhythmic drugs or amiodarone down to
00 beats/min; 2) one or more episodes of AFL docu-
ented within six months before enrollment; 3) two or
ore patient-reported symptoms of AFL during the previ-
us 12 months; 4) demonstration by endocardial recordings
f clockwise (CW) or counterclockwise (CCW) isthmus-
ependent type 1 AFL; and 5) age 80 years and 18
ears.
Enrollment in this study did not require failure of
nti-arrhythmic therapy for type 1 AFL. However, a history
f anti-arrhythmic therapy was obtained and reported.
reprocedural evaluation. Written, informed consent was
btained from all patients. A complete history was obtained,
ncluding demographic data, pertinent past medical history,
nd symptom and treatment history, and a physical exam-
nation was performed. A 12-lead electrocardiogram (ECG)
nd two-dimensional echocardiogram were obtained for
ach patient. A QOL questionnaire was completed by each
atient before ablation. Preprocedural anticoagulation with
arfarin was performed at the discretion of the investigator.
escription of procedure. PRE-ABLATION EVALUATION. Vas-
ular access was obtained via the femoral veins and right
nternal jugular vein (or left subclavian vein) by insertion of
- to 8-F sheaths, using the Seldinger percutaneous tech-
ique. Standard multi-electrode catheters were positioned
nder fluoroscopic guidance for activation mapping of the
ight atrium. Three-dimensional contact or non-contact
apping was allowed. Before ablation, each patient under-
ent a baseline electrophysiologic study during which in-
racardiac electrographic recordings were obtained from the
ight atrium, His bundle, coronary sinus, and right ventricle.
f the patient presented in sinus rhythm, the right atrial
ctivation sequence was mapped during pacing from the low
ateral right atrium and coronary sinus ostium to verify
idirectional conduction across the TV-IVC isthmus. Atrial
utter was then induced with rapid atrial pacing to confirm
he diagnosis of isthmus-dependent type 1 AFL. If the
atient presented in AFL, the presence of isthmus-
ependent flutter was documented by mapping, demon-
Abbreviations and Acronyms
AFL  atrial flutter
CCW counterclockwise
CW  clockwise
IVC  inferior vena cava
QOL  quality of life
RF  radiofrequency
TV  tricuspid valvetrating CCW or CW reentry around the tricuspid valve pnnulus, as well as concealed entrainment during pacing in
he TV-IVC isthmus.
BLATION PROCEDURE. Ablation was performed during
inus rhythm or AFL, using either an 8-mm (straight or
ontoured tip) or 10-mm (straight tip) tipped investiga-
ional electrode catheter. The electrode tip size used in each
ase was determined by the investigator at each site in a
onrandomized manner, with instructions from the sponsor
o utilize approximately equal numbers of both 8- and
0-mm electrode tip catheters at each study site. Using
ither an interrupted or continuous drag technique from the
V annulus to the IVC, ablation was performed beginning
t a power of 50 W (maximum of 100 W), for up to 120 s,
ith a maximum target temperature of 70°C. After each
ttempted isthmus ablation, the presence or absence of
idirectional isthmus conduction block was assessed during
acing from the coronary sinus ostium and low lateral right
trium at a cycle length 600 ms. Ablation was repeated
ntil isthmus block was achieved or the investigator deter-
ined that ablation using the investigational device was
nsuccessful. Bidirectional isthmus block was confirmed by
emonstrating a fully descending wavefront of activation in
he contralateral atrial wall during pacing from the coronary
inus ostium and low lateral right atrium, respectively.
dditional criteria confirming bidirectional isthmus block
ncluded recording of double potentials at the TV-IVC
sthmus during pacing from the coronary sinus ostium and
ow lateral right atrium. Anticoagulation with heparin
uring the procedure was performed at the discretion of the
nvestigator.
OST-ABLATION EVALUATION. After ablation, assessment
f TV-IVC isthmus conduction was performed periodically
or up to 30 min to ensure persistent isthmus block. Burst
acing was also performed at cycle lengths down to 2:1
apture or to a minimum cycle length of 180 ms from the
ow lateral right atrium and coronary sinus ostium to
onfirm that AFL was not inducible. If type 1 AFL (CW or
CW) was re-induced or resumption of unidirectional or
idirectional TV-IVC isthmus conduction was demon-
trated, ablation was repeated in the same or an alternate
ocation in the isthmus until isthmus block was achieved
nd AFL was no longer inducible, or the investigator
etermined that the procedure was unsuccessful using the
nvestigational device.
ostprocedural evaluation. All patients were evaluated by
epeat ECG and two-dimensional echocardiography within
2 h after ablation. All patients were instructed to use a
atient-activated event monitor (LifeWatch, Chicago, Illi-
ois) to telephonically transmit a rhythm strip weekly and
or any symptoms suggesting arrhythmia recurrence. After
blation, anticoagulation with warfarin was performed at
he discretion of the investigator.
Each patient was evaluated in the clinic at one, three, and
ix months after ablation. During all follow-up visits,
atients were interviewed for anti-arrhythmic and cardiac
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Ablation of AFL With Large-Tip Catheters April 21, 2004:1466–72edication use. At the one, three, and six-month follow-up
isits, a physical examination and 12-lead ECG were
erformed. At each evaluation, careful attention was given
o event monitor recordings, hospital or emergency room
isits, and any cardiovascular events that may have occurred
ince ablation. In addition, each patient was contacted by
elephone at 12 and 24 months and asked a series of
uestions regarding any recurrence of arrhythmia-related
ymptoms and any change in medical condition that would
ndicate a possible AFL recurrence or adverse event.
Each patient was asked to complete three health-related
OL survey instruments on a regular basis during the
tudy. These surveys were administered upon study entry
baseline) and at one, three, and six months after ablation.
hese surveys included the following: 1) the Short-Form 36
SF-36), a 36-item survey characterizing the patient’s gen-
ral health and well being; 2) the Symptom Assessment
urvey, a nine-item instrument relating to symptomatology;
nd 3) the Global Health Assessment, a single-item visual
nalog scale used to assess the patient’s overall health.
rimary efficacy end points. Short-term success was de-
ned as bidirectional isthmus block with no inducible type
AFL, achieved using only the investigational device.
ong-term success was defined as continued absence of type
AFL for six months after ablation.
econdary efficacy end points. Technical success was de-
ned as bidirectional isthmus block with no inducible type
AFL after ablation, using either the investigational device
r a standard device. Case and fluoroscopy times consistent
ith those reported in the medical literature. Demonstra-
ion that different tip configurations provide similar techni-
al success rates. Change or improvement from baseline in
OL scores.
afety end points. The primary safety end point was
ccurrence of a major complication, defined as a serious
dverse event occurring within seven days of the index
rocedure.
Other methods used to assess patient safety included
eekly event monitor transmissions, clinical assessments at
ne, three, and six months, and event monitor transmissions
riggered by symptoms.
A Clinical Events Committee provided input in the
eview and evaluation of reported adverse events. A Data
afety Monitoring Board periodically reviewed safety data
o determine the risk and benefit of the study treatment.
tatistical analysis. The study was a single-arm trial to
valuate the safety and efficacy of the EPT-1000 XP
ardiac Ablation System for treatment of type 1 AFL. The
tudy sample size provided 80% power for evaluating short-
erm success, complication rate, and six-month success.
dditional subgroup analyses are presented along with their
orresponding p values.
All statistical analyses were done using SAS Version 8
oftware (SAS Institute Inc., Cary, North Carolina). Pa-
ient demographics, clinical history, risk factors, pre- and
ost-procedural lesion characteristics, procedural character- hstics, and outcome variables were summarized using de-
criptive statistics for continuous variables (e.g., mean 
D) and frequency tables or proportions for discrete vari-
bles.
Multivariable model analyses were performed using lo-
istic regression to examine covariates as possible predictors
f short-term success, complication rate, and six-month
uccess. The covariates used were gender and a history of
eart disease, thromboembolic events, and stroke. A for-
ard model building procedure was used to determine
hich covariates were possible predictors of the primary end
oints listed previously. In addition, these covariables were
ndividually tested for univariable association with the pri-
ary end points, using the Fisher exact test with two-tailed
ignificance.
Differences between 8- and 10-mm tip ablation elec-
rodes were evaluated for short-term success, complication
ate, six-month success, number of ablations required, and
rocedure and fluoroscopy times, using the Fisher exact test
nd the Wilcoxon rank-sum test with two-tailed signifi-
ance.
Furthermore, an analysis was performed to identify any
ssociation between use of high power and occurrence of
ajor device-related complications, using both the Fisher
xact test and logistic regression.
ESULTS
atient population. A total of 1,076 patients with a diag-
osis of AFL were screened for the study, 169 of whom met all
nclusion criteria and were enrolled (Table 1). There were 138
82%) male and 31 (18%) female patients enrolled in the study,
ith an average age of 61  12 years. Nearly one-half (82
49%] of 169) reported a history of structural heart disease.
inety-five (56%) patients had left atrial enlargement, 47
28%) had right atrial enlargement, 40 (23%) had left ventric-
lar enlargement, and 23 (14%) had right ventricular enlarge-
ent. Preprocedural left ventricular ejection fraction was
50% in 112 (66%) patients,50% in 41 (24%) patients, and
ot evaluated in 16 (9%) patients. Thirty-nine (23%) patients
able 1. Clinical Characteristics of Patients (n  169)
ge (yrs) 61  12
ender (M/F) 138/31
tructural heart disease 82 (49%)
AE 95 (56%)
AE 47 (28%)
VEF 50%* 112 (66%)
VEF 50% 41 (24%)
rior AA drugs (class I or III) 39 (23%)
CW type 1 AFL† 129 (76%)
W type 1 AFL 31 (18%)
CW and CW type 1 AFL 4 (3%)
LVEF not evaluated in 16 patients (9%). †Morphology of AFL was not documented
efore ablation in 5 patients (3%). Data are presented as the mean value  SD or
umber (%) of patients.
AA  anti-arrhythmic; AFL  atrial flutter; CCW  counterclockwise; CW 
lockwise; LAE  left atrial enlargement; LVEF  left ventricular ejection fraction;
AE  right atrial enlargement.ad been treated with a class I-A, I-C, or III anti-arrhythmic
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April 21, 2004:1466–72 Ablation of AFL With Large-Tip Cathetersrug in the past, whereas 130 (77%) patients had received no
revious treatment. At the time of ablation, 42 (24%) patients
ere receiving a class I-A, I-C, or III anti-arrhythmic drug,
hereas 127 (75%) patients were not being treated. Thirty-two
19%) patients reported a history of atrial fibrillation, for which
he average interval between the last treatment and the inves-
igational procedure was 105 days. Patients were excluded if
hey had been treated for non-AFL arrhythmias within three
onths before the procedure. On the ECG, immediately
efore ablation, 95 (56%) patients were noted to be in AFL, 72
43%) in sinus rhythm, 1 (1%) in atrial tachycardia, and 1 (1%)
n atrial fibrillation (induced during electrophysiologic study).
ounterclockwise AFL was present or induced in 129 (76%)
atients before ablation, 31 (18%) patients had CW AFL, and
(3%) had both. In 5 (3%) patients, the morphology of AFL
as not documented on case-report forms.
igure 1. Flow diagram showing short- and long-term treatment outcom
ollow-up period was six months. †Bidirectional isthmus block and no i
ecurrence reported during six-month follow-up. §Anti-arrhythmic drugs re
ollow-up not related to the procedure. AA  anti-arrhythmic medicationAnticoagulation was prescribed according to standards at aach investigative center, rather than by protocol require-
ent. Thus, warfarin was administered before ablation in
nly 43% of patients and at discharge in 55% of patients.
arfarin therapy was then continued in 56%, 45%, and 30%
f patients at 1-, 3-, and 6-month follow-up, respectively.
ntravenous heparin was used in only 22% of patients during
blation.
hort-term results of ablation. In this study, 158 (93%) of
69 patients achieved short-term success (Fig. 1), whereas
he procedure failed in 11 (7%) patients. The mean proce-
ure time was 2.03  1.12 h, with a mean ablation time of
9.0  41.4 min and a mean fluoroscopy time of 28.4 
9.5 min.
A mean of 12 11 RF energy applications were delivered
er patient. The median number of RF applications needed
o terminate AFL was three. The median number of RF
atrial flutter (AFL) ablation with 8- or 10-mm electrode catheters. The
ble AFL after ablation using only the investigational device. ‡No AFL
d for arrhythmia other than AFL. Four deaths occurred during six-month
non-AFL rhythms; AFIB  atrial fibrillation.es of
nduci
quire
forpplications required to achieve bidirectional isthmus block
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Ablation of AFL With Large-Tip Catheters April 21, 2004:1466–72as 7, and 75% of patients had bidirectional isthmus block
chieved with 13 or fewer RF applications. The median
umber of RF applications delivered per patient was nine,
ith the 75th percentile at 16 lesions, and 25% of patients
ad three or more “insurance burns” (i.e., lesions delivered
fter bidirectional block was achieved). The mean duration
f each RF application was 73  37 s. The mean power
etting used was 78  17 W, whereas the mean power
ctually delivered to achieve the target temperature was 55
20 W. The mean temperature setting used was 64 8°C,
hereas the mean temperature actually achieved was 54 
°C.
The procedure was performed in the majority of patients
150 [89%] of 169), with only one investigational catheter.
wo investigational catheters were used in 14 (8%) patients,
nd three catheters were used in 5 (3%) patients. The
easons for the use of multiple catheters during a procedure
ncluded investigator preference, differences in patient anat-
my, stability in positioning, and the need for different
atheter sizes.
For patients in whom only one catheter was used to
chieve short-term success (n  150), the 10-mm straight-
ip catheter was used most often (49%), followed by the
-mm straight-tip catheter (35%), and lastly, the 8-mm
ontoured tip catheter (17%). There was no significant
ifference in short-term efficacy between these three abla-
ion electrodes: 69 (95%) of 73 patients with the 10-mm
traight tip, 51 (98%) of 52 patients with the 8-mm straight
ip, and 24 (96%) of 25 patients with the 8-mm contoured
ip (p  NS). However, the mean number of RF applica-
ions required to achieve short-term success was 10  8
ith the 10-mm tip versus 14  8 with the 8-mm tip (p 
.002). The mean time required for ablation was 0.5 0.4 h
ith the 10-mm tip versus 0.8  0.6 h with the 8-mm tip
p  0.0002). Data using the 8-mm contoured tip catheter
ere not included in this statistical analysis, because these
5 patients were treated at a single institution, which would
ot allow for a fair comparison of results across the entire
Table 2. Summary of Health-Related Quality-
Up for All Patients Evaluated at Six Months
Item Baseline 3
Physical component summary 42.4
Physical functioning 68.6
Role—physical 42.9
Bodily pain 72.7
General health 66.7
Mental component summary 50.0
Vitality 51.4
Social functioning 74.3
Role—emotional 71.3
Mental health 75.7
Feeling thermometer 70.7
Severity 25.3
Frequency 27.7
*Average of follow-up values determined at three- and six-mo
and follow-up values.tudy population. At this institution, successful ablation sith the contoured tip required a mean of 6  5 RF
pplications and a mean ablation time of 0.3  0.3 h.
nalysis of the effect of maximum applied power on
hort-term success, as well as the number or duration of RF
pplications, revealed no significant difference between de-
iles from 50, 50 to 60, 60 to 70, or 70 W delivered.
At the conclusion of the ablation procedure, 96% of patients
ere in normal sinus rhythm. In patients who had the A-H
nterval measured both before and after ablation, there was no
ignificant difference (90.7 28.2 ms vs. 90.9 27.5 ms). The
-V interval was also not significantly different before and
fter ablation (50.5  13.7 ms vs. 50.9  17.0 ms).
ong-term results of ablation. Of the 158 patients with
hort-term success (Fig. 1), 42 patients were not evaluated for
ong-term success at six months because of either use of
nti-arrhythmic drugs for treatment of recurrent arrhythmias
ther than AFL (n 20), death (n 4), bradycardia requiring
acemaker implantation (n  11), persistent atrial fibrillation
n 1), voluntary withdrawal from the study (n 4), or a lack
f follow-up (2). Of the 116 patients who were evaluated at six
onths, 112 (97%) had no recurrence of AFL. There was no
entricular tachycardia documented in any patient. These
esults were derived from both symptom-triggered and sched-
led event monitor transmissions, for which there was high
ompliance in 96% of patients (defined as transmission
chieved during at least two-thirds of all scheduled follow-up
vents).
In addition, among the 112 patients evaluated at six
onths who had no AFL recurrence, telephone contact at
2 and 24 months revealed that 95% (93 of 98 patients) and
3% (78 of 84 patients), respectively, remained free of
rrhythmia-related symptoms.
ffects of AFL ablation on QOL. The ablation of AFL in
his study population resulted in a statistically significant
mprovement in QOL scores at three- and six-month
ollow-up (Table 2), including seven of 10 items contained
n the SF-36 survey (p  0.05), the Global Health Assess-
ent survey (p  0.01), and the Symptom Assessment
ife Instrument Scores at Baseline and Follow-
hs 6 Months Follow-Up* p Value†
46.1 45.9 0.0001
76.2 76.2 0.0005
67.3 66.8  0.0001
72.4 73.3 0.74
68.5 68.8 0.24
51.7 52.1 0.016
60.0 60.8  0.0001
85.6 83.8 0.0001
74.3 77.3 0.12
78.5 79.2 0.029
78.2 78.4  0.0001
4.8 5.7  0.0001
6.4 7.6  0.0001
sits. †The p values represent the difference between baselineof-L
Mont
46.9
76.4
73.5
76.8
69.7
52.8
62.2
86.2
80.3
80.5
79.6
6.0
7.5
nth viurvey (p  0.01). Among the 158 patients with short-term
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April 21, 2004:1466–72 Ablation of AFL With Large-Tip Cathetersuccess, there was a significant reduction (p  0.03) in
nti-arrhythmic drug use at six months after ablation, from
9 (25%) to 19 (15%) patients. Among the 112 patients
ith no recurrence of AFL at six months, there was also a
eduction in anti-arrhythmic drug use, from 23 to 0 patients
t six months after ablation. Among the 158 patients with
hort-term success in ablation of AFL, at six months after
blation there was a significant reduction (p  0.05) in the
umber of patients taking rate-control drugs (i.e., beta-
lockers, calcium channel blockers, and digitalis glycosides),
rom 85 (54%) to 43 (34%) patients. Among the 112
atients with no recurrence of AFL, at six months after
blation there was a significant reduction (p  0.05) in the
umber of patient taking rate-control drugs, from 58 (52%)
o 34 (31%) patients.
dverse events associated with ablation of AFL. There
ere eight major adverse events in 6 (3.6%) of the 169 patients
reated in this study. These major adverse events included
ulmonary embolism (n  1), fractured femur (n  1),
ilateral lower extremity ischemia due to systemic thrombo-
mbolism (n 1), deep venous thrombosis (n 1), right groin
ematoma (n  1), cerebral embolus with resolution of
eurologic findings (n  1), and cerebral infarct (thrombotic)
ve days after the procedure with persistent mild aphasia (n
). Of these major adverse events, the femur fracture (due to an
ccidental fall) was not caused by the study procedure, and the
erebral embolus and cerebral infarct were associated with a left
trial ablation procedure and intracranial stenosis of right and
eft middle cerebral arteries, respectively. There were no deaths
ttributable to the study.
Statistical analysis demonstrated no correlation between
hese major adverse events and use of high power during
blation (i.e., 60 W), ablation electrode size, presence of
nderlying structural heart disease, stroke, age, or a history
f atrial fibrillation. However, there was a significant cor-
elation between the occurrence of a major adverse event
nd a history of thromboembolic events (p  0.0488).
ISCUSSION
he results of this study indicate that ablation of type 1
FL using 8- or 10-mm electrode-tipped ablation cathe-
ers, with a higher power RF energy generator capable of
elivering up to 100 W, is safe and highly effective. The data
lso demonstrate that the 10-mm ablation electrode cathe-
er may allow ablation of AFL to be performed more rapidly
nd with fewer RF applications compared with the 8-mm
blation electrode catheter.
hort- and long-term efficacy of large-tip ablation cath-
ters for the cure of AFL. The results of this study confirm
hat a high degree of short- and long-term success can be
chieved using 8- or 10-mm electrode-tipped ablation
atheters with a high- power 100-W RF generator to ablate
ype 1 AFL. The short- (93%) and long-term (97%)
fficacy, ablation and procedure times, number of RF
pplications, and total duration of RF application observed gn this study were comparable to, or better than, those
chieved in most recently published studies reporting suc-
ess rates ranging from 85% to 90% using standard 4- to
-mm ablation electrode catheters (1–8), as well as 8-mm or
rrigated ablation electrode catheters (9–13), with standard
0-W RF generators. Furthermore, this study demonstrated
hat ablation of AFL required fewer RF applications and a
horter duration of ablation with the 10-mm electrode
blation catheter compared with the 8-mm electrode abla-
ion catheter. Thus, in addition to the comparable or
lightly greater efficacy of the large-tip ablation catheters
nd high-power RF generator used in this study, there are
urther potential advantages of fewer RF applications and
horter total ablation time required with the 10- versus
-mm electrode ablation catheter.
mpact of AFL ablation on QOL measures. Curative
blation of AFL produced significant improvements in
OL measures, including overall sense of well-being and
eneral health, and a reduction of arrhythmia-related symp-
oms. Similar findings have been observed in previous
tudies (16–18). In addition, ablation of AFL was shown to
ignificantly reduce the use of anti-arrhythmic and rate-
ontrol drugs compared with baseline, despite the fact that
ome rate-control drugs may also be used to control
ypertension.
dverse events related to use of large-tip ablation elec-
rodes and high-power RF generator. The major adverse
vent rate (3.6%) in this study was low compared with the
ates observed in previous studies for ablation of AFL and
ther forms of supraventricular tachycardia (1–14,19,20).
his low adverse event rate was observed despite the
pproximately equal use of 8- and 10-mm electrode-tipped
blation catheters and delivery of power in excess of 70 W
n many cases. In fact, statistical analysis revealed no
orrelation between the level of power delivered during
blation and the occurrence of adverse events. Thus, the
ata clearly indicate that ablation of AFL with large
blation electrodes and a high-power RF generator is at
east as safe as ablation with the standard RF catheters and
enerators currently in use today (1–14,19,20).
Although weak, a statistically significant correlation was
bserved between a history of thromboembolism and the
ccurrence of major adverse events, a majority of which were
hromboembolic in nature. This observation raises concerns
hat patients should probably be anticoagulated with war-
arin before and for several months after AFL ablation, in
rder to minimize the risk for thromboembolic complica-
ions. Again, however, there was no correlation between the
ccurrence and type of adverse events and the use of
arge-tip catheters or high power during ablation.
tudy limitations. This multicenter, prospective registry
tudy was not designed as a randomized comparative study,
hich would have allowed a comparison of safety and
fficacy between the EPT-1000 XP Cardiac Ablation Sys-
em using large-tip ablation catheters plus a 100-W RF
enerator and the standard 4- to 5-mm ablation electrode
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owever, despite the very high efficacy and low adverse
vent rates observed in this study, compared with the similar
r only slightly inferior results in recently published studies
sing standard systems, there probably would not have been
statistically significant difference in the results.
onclusions. Ablation of AFL using an 8- or 10-mm
blation electrode catheter and high-power 100-W RF
enerator was highly effective, with short- and long-term
uccess rates of 93% and 97%, respectively. The maximum
ower required to maintain a target temperature during
blation of AFL with an 8- or 10-mm ablation electrode
atheters was frequently high in this study, with a maximum
ower over 70 W required in 85% of patients. Additionally,
he 10-mm ablation electrode catheter required a greater
aximum power compared with the 8-mm ablation elec-
rode catheter. Ablation of AFL with an 8- or 10-mm
blation electrode catheter and high-power 100-W RF
enerator was safe, with a complication rate of only 3.6%.
he use of large 8- or 10-mm ablation electrode catheters
educed the ablation and procedure times, number of RF
pplications required, and total duration of energy applica-
ion, compared with most published studies using standard
- to 5-mm ablation electrode catheters. The number of RF
nergy applications and the total duration of RF application
equired to cure AFL was significantly lower with the 10-
ersus 8-mm ablation electrode catheter. Quality-of-life
easures were significantly improved after catheter ablation
f AFL.
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